Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.34 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15804255 | 0.81 | CYP3A4 (0.39) | TDP1ATMVCAM1ALDH1A1KMT2A | |
| SCHEMBL4762697 | 0.78 | TDP1 (0.46) | TDP1ATMVCAM1ALDH1A1HIF1A | |
| SCHEMBL30563095 | 0.76 | HSD17B10 (0.50) | TDP1ALDH1A1LMNAMAPTHTT | |
| SCHEMBL741363 | 0.76 | ALDH1A1 (0.36) | TDP1VCAM1ALDH1A1KMT2AMEN1 | |
| SCHEMBL10547254 | 0.76 | GPR35 (0.46) | TDP1ALDH1A1HIF1AKMT2AMEN1 | |
| SCHEMBL172188 | 0.76 | HSD17B10 (0.50) | TDP1ALDH1A1LMNAMAPTHTT | |
| SCHEMBL8568031 | 0.76 | TDP1 (0.47) | TDP1ALDH1A1KMT2AMEN1CASP6 | |
| SCHEMBL3059949 | 0.76 | TSHR (0.47) | TDP1VCAM1F2PRSS1PRSS2 | |
| SCHEMBL10645218 | 0.76 | VCAM1 (0.44) | TDP1VCAM1ALDH1A1KMT2AMEN1 | |
| SCHEMBL16067605 | 0.74 | MAPT (0.44) | TDP1ALDH1A1KMT2AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4443457-A | Aminocrot onylpyridine N-oxides useful as adjuncts to radiation therapy | MERCK & CO., INC. (US) | 1984-04-17 | — | — | US | claimed |
| US-12384777-B2 | Compounds comprising N-methyl-2-pyridone, and pharmaceutically acceptable salts | Tay Therapeutics Limited (GB) | 2025-08-12 | — | — | US | disclosed |
| EP-4538270-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Sapiensbio Inc. (KR) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025034810-A1 | SYNTHESES AND USE OF POTASSIUM CHANNEL BLOCKERS IN PET IMAGING AND IN THERAPEUTICS | THE GENERAL HOSPITAL CORPORATION (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2023239227-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | 주식회사 사피엔스바이오 | 2023-12-14 | — | — | WO | disclosed |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-11530208-B2 | Imidazo[4,5-C]pyridine derived SSAO inhibitors | PROXIMAGEN, LLC (US) | 2022-12-20 | — | — | US | disclosed |
| US-20220204500-A1 | COMPOUNDS COMPRISING N-METHYL-2-PYRIDONE, AND PHARMACEUTICALLY ACCEPTABLE SALTS | UNIVERSITY OF DUNDEE (GB) | 2022-06-30 | — | — | US | disclosed |
| CN-113924298-A | Compounds comprising N-methyl-2-pyridone and pharmaceutically acceptable salts | 邓迪大学 | 2022-01-11 | — | — | CN | disclosed |
| US-10968223-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PROXIMAGEN, LLC (US) | 2021-04-06 | — | — | US | disclosed |
| US-4931457-A | Naphthylamino-and naphthyloxy-pyridinamine comounds useful as topical antiinflammatory agents for the treatment of skin disorders | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1990-06-05 | — | — | US | disclosed |
| US-4880822-A | COGNITION ACTIVATORS, ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1989-11-14 | — | — | US | disclosed |
| US-4792562-A | N-(pyrrol-1-yl)pyridinamines having memory enhancing activity | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1988-12-20 | — | — | US | disclosed |
| EP-0287982-A2 | N-(Pyridinyl)-1H-indol-1-amines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1988-10-26 | — | — | EP | disclosed |
| US-4767698-A | PHOTOSTABILITY, HEAT RESISTANCE | AGFA-GEVAERT AKTIENGESELLSCHAFT (DE) | 1988-08-30 | — | — | US | disclosed |
| EP-0226099-A2 | N-(pyrrol-1-yl)pyridinamines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1987-06-24 | — | — | EP | disclosed |
| US-4443457-A | Aminocrot onylpyridine N-oxides useful as adjuncts to radiation therapy | MERCK & CO., INC. (US) | 1984-04-17 | — | — | US | disclosed |
| US-4225713-A | HYPOTENSIVE AGENTS | FREED MEIER E | 1980-09-30 | — | — | US | disclosed |
| US-4179563-A | COGNITION ACTIVATORS | WARNER-LAMBERT COMPANY (US) | 1979-12-18 | — | — | US | disclosed |
| US-4138564-A | HYPOTENSIVE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204500-A1 | COMPOUNDS COMPRISING N-METHYL-2-PYRIDONE, AND PHARMACEUTICALLY ACCEPTABLE SALTS | TPMT, IL5, P2RY6 | TDP1 1945/4885ATM 1970/4885VCAM1 1497/4885 |
| US-10968223-B2 | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as SSAO inhibitors | PNPO, PPOX, SCO2 | TDP1 2979/4885ATM 2195/4885VCAM1 1121/4885 |
| US-20230271941-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | TDP1 75/4885ATM 110/4885VCAM1 2789/4885 |
| US-11530208-B2 | Imidazo[4,5-C]pyridine derived SSAO inhibitors | PNPO, SQOR, HAO1 | TDP1 1487/4885ATM 1567/4885VCAM1 1664/4885 |
| US-12384777-B2 | Compounds comprising N-methyl-2-pyridone, and pharmaceutically acceptable salts | TPMT, IL5, P2RY6 | TDP1 1945/4885ATM 1970/4885VCAM1 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.